Sykes opens Chiltern’s new global headquarters
September 1, 2004Leading independent clinical research organisation (CRO) Chiltern International has opened its new global headquarters in Slough.Guest of honour Sir Richard …
Online prescriptions given go-ahead as part of reforms
September 1, 2004The opening of online pharmacies has been given the go-ahead by the UK government, signalling the latest phase of a …
No food or drink restrictions for new HIV treatment
September 1, 2004GlaxoSmithKline has launched Telzir in the UK, a new protease inhibitor for HIV patients and the first ever to have …
GSK settles US antidepressant lawsuit with $2.5 million
September 1, 2004GlaxoSmithKline has paid $2.5 million to the State of New York in an out-of-court settlement of the lawsuit alleging it …
Alarm raised over counterfeit Cialis
August 26, 2004Patients taking Cialis have been warned that counterfeit versions of the impotence drug are in circulation in the UK, the …
Cymbalta launched amid renewed controversy
August 26, 2004Lilly has launched its new depression treatment Cymbalta in the US, a blockbuster tipped to earn $2 billion by 2008.Cymbalta …
Novartis claims Prexige safety advantage over rivals
August 26, 2004Novartis is preparing its latest blockbuster candidate Prexige for launch around the world by proclaiming its superior side-effect profile to …
Barker named new ABPI chief
August 12, 2004Dr Richard Barker has been named as successor to Dr Trevor Jones as the ABPI's director general.Dr Jones, who has …
Novartis to ace competition in new hypertension class
August 12, 2004Novartis is expected to take the lead in the newest class of hypertension treatments when it launches aliskiren in 2006.Analysts …
MabThera use to double with first line indication
August 11, 2004Roche's cancer drug MabThera (rituximab) has received European approval for a new indication – the first line treatment of indolent …
Developing people developing drugs
August 9, 2004What distinguishes pharma research and development from other high-tech industries? It is an oddity of pharma research R&D that, despite …
